Cequent Says In-House IBD Candidate Will Likely Move to Clinic Before Novartis-Optioned Rx

The company also remains on track with its more advanced familial adenomatous polyposis drug and plans to file within the next two weeks an investigational new drug application to begin testing the therapy in humans.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories